| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Non-alcoholic Fatty Liver Disease | 95 | 2024 | 212 | 31.140 |
Why?
|
| Liver Cirrhosis | 37 | 2024 | 297 | 6.200 |
Why?
|
| Fatty Liver | 16 | 2024 | 125 | 4.610 |
Why?
|
| Liver Transplantation | 24 | 2024 | 1268 | 3.930 |
Why?
|
| Fibroblast Growth Factors | 5 | 2023 | 80 | 2.790 |
Why?
|
| Liver | 26 | 2024 | 1230 | 2.770 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2024 | 1373 | 2.110 |
Why?
|
| Humans | 123 | 2024 | 86643 | 1.680 |
Why?
|
| Disease Progression | 12 | 2023 | 1531 | 1.530 |
Why?
|
| Chenodeoxycholic Acid | 5 | 2021 | 6 | 1.380 |
Why?
|
| Risk Factors | 26 | 2023 | 5417 | 1.160 |
Why?
|
| Obesity | 16 | 2023 | 963 | 1.120 |
Why?
|
| Global Health | 5 | 2023 | 193 | 1.080 |
Why?
|
| Metabolic Syndrome | 4 | 2023 | 141 | 1.080 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 827 | 1.060 |
Why?
|
| Gastroenterologists | 2 | 2023 | 30 | 1.060 |
Why?
|
| Life Style | 4 | 2019 | 189 | 1.010 |
Why?
|
| Bariatric Surgery | 4 | 2017 | 194 | 0.990 |
Why?
|
| Delphi Technique | 5 | 2024 | 80 | 0.980 |
Why?
|
| Carcinoma, Hepatocellular | 7 | 2024 | 384 | 0.980 |
Why?
|
| Consensus | 8 | 2024 | 335 | 0.970 |
Why?
|
| Liver Diseases | 4 | 2024 | 238 | 0.950 |
Why?
|
| Gastrointestinal Agents | 2 | 2023 | 161 | 0.950 |
Why?
|
| Diet | 5 | 2019 | 443 | 0.940 |
Why?
|
| Double-Blind Method | 15 | 2024 | 1823 | 0.920 |
Why?
|
| Prevalence | 12 | 2020 | 1239 | 0.870 |
Why?
|
| Micronutrients | 2 | 2013 | 17 | 0.870 |
Why?
|
| Weight Loss | 4 | 2022 | 229 | 0.850 |
Why?
|
| Physicians, Primary Care | 1 | 2023 | 104 | 0.850 |
Why?
|
| Liver Neoplasms | 7 | 2024 | 736 | 0.840 |
Why?
|
| Female | 44 | 2024 | 44532 | 0.840 |
Why?
|
| Hypoglycemic Agents | 4 | 2019 | 378 | 0.830 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 378 | 0.830 |
Why?
|
| Treatment Outcome | 24 | 2024 | 7993 | 0.820 |
Why?
|
| Biomarkers | 11 | 2023 | 1718 | 0.800 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 1169 | 0.770 |
Why?
|
| Biopsy | 12 | 2024 | 1163 | 0.770 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2024 | 1961 | 0.760 |
Why?
|
| Steroids | 1 | 2021 | 177 | 0.760 |
Why?
|
| Anticholesteremic Agents | 2 | 2018 | 137 | 0.730 |
Why?
|
| Exercise | 5 | 2018 | 315 | 0.730 |
Why?
|
| Hepatomegaly | 3 | 2023 | 15 | 0.700 |
Why?
|
| Male | 40 | 2024 | 40965 | 0.700 |
Why?
|
| Risk Assessment | 12 | 2023 | 2261 | 0.690 |
Why?
|
| Sarcopenia | 1 | 2019 | 13 | 0.690 |
Why?
|
| Rosuvastatin Calcium | 1 | 2018 | 29 | 0.680 |
Why?
|
| Insulin Resistance | 7 | 2018 | 377 | 0.670 |
Why?
|
| Choline Deficiency | 3 | 2011 | 4 | 0.670 |
Why?
|
| Thiazolidinediones | 2 | 2016 | 82 | 0.670 |
Why?
|
| Epidemics | 4 | 2021 | 33 | 0.650 |
Why?
|
| Methionine | 3 | 2011 | 66 | 0.650 |
Why?
|
| United States | 18 | 2022 | 6672 | 0.630 |
Why?
|
| Adult | 29 | 2024 | 25648 | 0.580 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2017 | 104 | 0.580 |
Why?
|
| Middle Aged | 30 | 2024 | 25028 | 0.560 |
Why?
|
| Alanine Transaminase | 6 | 2019 | 73 | 0.560 |
Why?
|
| Comorbidity | 7 | 2023 | 943 | 0.560 |
Why?
|
| Diabetes Complications | 2 | 2015 | 207 | 0.550 |
Why?
|
| Pentoxifylline | 2 | 2016 | 9 | 0.550 |
Why?
|
| Severity of Illness Index | 10 | 2023 | 1801 | 0.550 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2021 | 122 | 0.550 |
Why?
|
| Fibrosis | 6 | 2024 | 203 | 0.540 |
Why?
|
| Coronary Stenosis | 1 | 2016 | 39 | 0.540 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 1621 | 0.530 |
Why?
|
| End Stage Liver Disease | 3 | 2023 | 61 | 0.530 |
Why?
|
| Hepatitis C, Chronic | 2 | 2019 | 126 | 0.530 |
Why?
|
| HIV Infections | 1 | 2023 | 772 | 0.500 |
Why?
|
| Coronary Angiography | 1 | 2016 | 232 | 0.500 |
Why?
|
| Incretins | 1 | 2014 | 14 | 0.500 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 114 | 0.500 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2014 | 19 | 0.490 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2014 | 48 | 0.490 |
Why?
|
| Hypertension, Portal | 3 | 2019 | 47 | 0.480 |
Why?
|
| Vitamin E | 3 | 2019 | 35 | 0.450 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2012 | 23 | 0.440 |
Why?
|
| Placebos | 3 | 2021 | 218 | 0.440 |
Why?
|
| Pregnancy Complications | 2 | 2013 | 336 | 0.420 |
Why?
|
| Mass Screening | 2 | 2017 | 618 | 0.420 |
Why?
|
| Hepatitis, Alcoholic | 3 | 2021 | 19 | 0.420 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1036 | 0.420 |
Why?
|
| Metformin | 3 | 2019 | 128 | 0.400 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2011 | 30 | 0.400 |
Why?
|
| Dietary Fats | 2 | 2012 | 135 | 0.400 |
Why?
|
| Public Health | 3 | 2023 | 129 | 0.400 |
Why?
|
| Unfolded Protein Response | 1 | 2011 | 39 | 0.400 |
Why?
|
| Terminology as Topic | 2 | 2023 | 217 | 0.390 |
Why?
|
| Ethanol | 2 | 2023 | 249 | 0.380 |
Why?
|
| Gastroenterology | 2 | 2024 | 134 | 0.380 |
Why?
|
| Pregnancy | 4 | 2017 | 2894 | 0.370 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2011 | 190 | 0.370 |
Why?
|
| Body Mass Index | 5 | 2020 | 770 | 0.370 |
Why?
|
| Postoperative Complications | 3 | 2019 | 2207 | 0.360 |
Why?
|
| Logistic Models | 6 | 2021 | 1186 | 0.340 |
Why?
|
| Imidazoles | 2 | 2020 | 162 | 0.340 |
Why?
|
| Sildenafil Citrate | 2 | 2019 | 22 | 0.330 |
Why?
|
| Leucine | 2 | 2019 | 67 | 0.330 |
Why?
|
| Living Donors | 2 | 2002 | 339 | 0.330 |
Why?
|
| Incidence | 6 | 2018 | 1577 | 0.330 |
Why?
|
| Europe | 4 | 2022 | 309 | 0.310 |
Why?
|
| Neoplasms | 1 | 2023 | 2898 | 0.310 |
Why?
|
| Alcohol Drinking | 5 | 2024 | 267 | 0.300 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2006 | 33 | 0.300 |
Why?
|
| Hepatic Encephalopathy | 2 | 2023 | 40 | 0.300 |
Why?
|
| Ventricular Remodeling | 2 | 2020 | 96 | 0.300 |
Why?
|
| Liver Function Tests | 3 | 2021 | 93 | 0.290 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2006 | 29 | 0.280 |
Why?
|
| Liver Failure, Acute | 1 | 2006 | 38 | 0.280 |
Why?
|
| Aspartate Aminotransferases | 2 | 2019 | 73 | 0.280 |
Why?
|
| Body Weight | 3 | 2023 | 459 | 0.270 |
Why?
|
| Diet Therapy | 2 | 2016 | 20 | 0.270 |
Why?
|
| Prospective Studies | 10 | 2024 | 4213 | 0.270 |
Why?
|
| Immunosuppressive Agents | 3 | 2018 | 977 | 0.270 |
Why?
|
| Retrospective Studies | 8 | 2023 | 8489 | 0.260 |
Why?
|
| Aged | 11 | 2022 | 18415 | 0.260 |
Why?
|
| Alcohol Abstinence | 3 | 2020 | 7 | 0.260 |
Why?
|
| Delivery, Obstetric | 2 | 2017 | 112 | 0.260 |
Why?
|
| Lipoproteins, VLDL | 2 | 2018 | 37 | 0.250 |
Why?
|
| Pyridazines | 1 | 2024 | 22 | 0.240 |
Why?
|
| Time Factors | 8 | 2021 | 5210 | 0.240 |
Why?
|
| Uracil | 1 | 2024 | 72 | 0.240 |
Why?
|
| Pathologists | 1 | 2023 | 24 | 0.240 |
Why?
|
| Lactulose | 1 | 2023 | 19 | 0.240 |
Why?
|
| International Classification of Diseases | 1 | 2024 | 69 | 0.230 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2003 | 40 | 0.230 |
Why?
|
| Metabolic Diseases | 1 | 2023 | 48 | 0.230 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2015 | 113 | 0.220 |
Why?
|
| Critical Care | 1 | 2006 | 370 | 0.220 |
Why?
|
| Administration, Oral | 2 | 2021 | 684 | 0.220 |
Why?
|
| Diabetes Mellitus | 4 | 2020 | 806 | 0.220 |
Why?
|
| Alcoholism | 1 | 2024 | 172 | 0.210 |
Why?
|
| Health Care Costs | 2 | 2022 | 238 | 0.210 |
Why?
|
| Signal Transduction | 2 | 2017 | 3241 | 0.210 |
Why?
|
| New Zealand | 1 | 2021 | 22 | 0.210 |
Why?
|
| France | 1 | 2021 | 47 | 0.210 |
Why?
|
| Germany | 1 | 2021 | 72 | 0.210 |
Why?
|
| Fatty Acid Synthase, Type I | 1 | 2021 | 1 | 0.210 |
Why?
|
| Graft Survival | 4 | 2019 | 884 | 0.210 |
Why?
|
| Lipogenesis | 1 | 2021 | 22 | 0.200 |
Why?
|
| United Kingdom | 1 | 2021 | 164 | 0.200 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 894 | 0.200 |
Why?
|
| Canada | 1 | 2021 | 204 | 0.200 |
Why?
|
| Survival Analysis | 3 | 2019 | 1538 | 0.200 |
Why?
|
| Triglycerides | 2 | 2018 | 232 | 0.200 |
Why?
|
| Lipids | 4 | 2021 | 269 | 0.200 |
Why?
|
| Nitriles | 1 | 2021 | 149 | 0.200 |
Why?
|
| Triazoles | 1 | 2021 | 96 | 0.190 |
Why?
|
| Isonicotinic Acids | 1 | 2020 | 1 | 0.190 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2003 | 229 | 0.190 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 1019 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 2271 | 0.190 |
Why?
|
| Health Services Needs and Demand | 1 | 2021 | 102 | 0.190 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 3640 | 0.190 |
Why?
|
| Azetidines | 1 | 2020 | 36 | 0.190 |
Why?
|
| Needs Assessment | 1 | 2021 | 154 | 0.190 |
Why?
|
| Pectins | 1 | 2019 | 5 | 0.180 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2019 | 2 | 0.180 |
Why?
|
| Sulfoxides | 1 | 2019 | 6 | 0.180 |
Why?
|
| Benzothiazoles | 1 | 2019 | 17 | 0.180 |
Why?
|
| Galectin 3 | 1 | 2019 | 17 | 0.180 |
Why?
|
| Piperidines | 1 | 2021 | 181 | 0.180 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2020 | 73 | 0.180 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 28 | 0.180 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2019 | 20 | 0.180 |
Why?
|
| Isoxazoles | 1 | 2019 | 77 | 0.180 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 16 | 0.180 |
Why?
|
| Analysis of Variance | 1 | 2021 | 912 | 0.180 |
Why?
|
| Education | 1 | 2019 | 58 | 0.170 |
Why?
|
| Benzamides | 1 | 2020 | 229 | 0.170 |
Why?
|
| Cholestenones | 1 | 2018 | 2 | 0.170 |
Why?
|
| Testosterone | 2 | 2019 | 271 | 0.170 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2019 | 9 | 0.170 |
Why?
|
| Weight Gain | 2 | 2017 | 123 | 0.170 |
Why?
|
| Awareness | 1 | 2019 | 93 | 0.170 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 426 | 0.170 |
Why?
|
| Population Surveillance | 1 | 2019 | 219 | 0.160 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 639 | 0.160 |
Why?
|
| Quality of Life | 3 | 2021 | 1585 | 0.160 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 165 | 0.160 |
Why?
|
| Pyridines | 1 | 2020 | 310 | 0.160 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2018 | 24 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 98 | 0.160 |
Why?
|
| Everolimus | 1 | 2017 | 40 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 3362 | 0.150 |
Why?
|
| Cholesterol, LDL | 1 | 2018 | 222 | 0.150 |
Why?
|
| Early Diagnosis | 2 | 2019 | 131 | 0.150 |
Why?
|
| Models, Biological | 2 | 2019 | 1749 | 0.150 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2017 | 59 | 0.150 |
Why?
|
| Australia | 3 | 2021 | 99 | 0.150 |
Why?
|
| Obstetric Labor Complications | 1 | 2017 | 34 | 0.150 |
Why?
|
| Stroke | 2 | 2018 | 965 | 0.150 |
Why?
|
| Hospitals, University | 1 | 2017 | 194 | 0.150 |
Why?
|
| Animals | 8 | 2023 | 26582 | 0.140 |
Why?
|
| Young Adult | 6 | 2020 | 5976 | 0.140 |
Why?
|
| Lipid Metabolism | 2 | 2012 | 196 | 0.140 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 153 | 0.140 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2016 | 9 | 0.140 |
Why?
|
| Heart Failure | 2 | 2018 | 1204 | 0.140 |
Why?
|
| Tacrolimus | 1 | 2017 | 373 | 0.140 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1805 | 0.140 |
Why?
|
| Internationality | 1 | 2016 | 69 | 0.140 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 592 | 0.140 |
Why?
|
| Pregnancy Outcome | 1 | 2017 | 247 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2016 | 80 | 0.130 |
Why?
|
| S-Adenosylmethionine | 1 | 2015 | 15 | 0.130 |
Why?
|
| Graft Rejection | 2 | 2018 | 1065 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 2501 | 0.130 |
Why?
|
| Adolescent | 7 | 2023 | 8981 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 508 | 0.130 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 288 | 0.130 |
Why?
|
| Mice | 6 | 2023 | 11352 | 0.130 |
Why?
|
| Hepacivirus | 2 | 2019 | 159 | 0.130 |
Why?
|
| Inflammation | 2 | 2023 | 920 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 469 | 0.130 |
Why?
|
| Chemoprevention | 1 | 2015 | 91 | 0.130 |
Why?
|
| Chicago | 2 | 2017 | 1379 | 0.130 |
Why?
|
| Leptin | 1 | 2015 | 105 | 0.130 |
Why?
|
| Antioxidants | 1 | 2016 | 223 | 0.130 |
Why?
|
| Recurrence | 4 | 2020 | 1139 | 0.130 |
Why?
|
| Liraglutide | 1 | 2014 | 5 | 0.130 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2015 | 83 | 0.130 |
Why?
|
| Heart Ventricles | 1 | 2020 | 760 | 0.130 |
Why?
|
| Toll-Like Receptors | 1 | 2015 | 92 | 0.120 |
Why?
|
| Insulin-Secreting Cells | 1 | 2018 | 397 | 0.120 |
Why?
|
| Child | 3 | 2023 | 6927 | 0.120 |
Why?
|
| Age Factors | 2 | 2018 | 1851 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 685 | 0.120 |
Why?
|
| Cause of Death | 1 | 2015 | 277 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2016 | 695 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 860 | 0.110 |
Why?
|
| Heart Block | 1 | 2012 | 32 | 0.110 |
Why?
|
| Perhexiline | 1 | 2012 | 1 | 0.110 |
Why?
|
| Hospitalization | 2 | 2022 | 849 | 0.110 |
Why?
|
| Amiodarone | 1 | 2012 | 12 | 0.110 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 30 | 0.110 |
Why?
|
| Diet, Reducing | 1 | 2012 | 31 | 0.110 |
Why?
|
| Dietary Proteins | 1 | 2012 | 30 | 0.110 |
Why?
|
| Dietary Carbohydrates | 1 | 2012 | 38 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 318 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1686 | 0.110 |
Why?
|
| Prognosis | 1 | 2020 | 3679 | 0.110 |
Why?
|
| Cannabis | 1 | 2012 | 34 | 0.100 |
Why?
|
| Occupational Diseases | 1 | 2012 | 55 | 0.100 |
Why?
|
| Sex Factors | 1 | 2015 | 1054 | 0.100 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2011 | 5 | 0.100 |
Why?
|
| Transcription Factor CHOP | 1 | 2011 | 15 | 0.100 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2011 | 15 | 0.100 |
Why?
|
| Animal Feed | 1 | 2011 | 20 | 0.100 |
Why?
|
| Choline | 1 | 2011 | 23 | 0.100 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2012 | 101 | 0.100 |
Why?
|
| Methotrexate | 1 | 2012 | 249 | 0.100 |
Why?
|
| Colic | 1 | 2011 | 7 | 0.100 |
Why?
|
| Intestinal Diseases | 1 | 2012 | 79 | 0.100 |
Why?
|
| Protein Phosphatase 1 | 1 | 2011 | 34 | 0.100 |
Why?
|
| Asia | 2 | 2021 | 95 | 0.100 |
Why?
|
| Dyslipidemias | 1 | 2012 | 109 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2012 | 187 | 0.100 |
Why?
|
| Mice, Mutant Strains | 1 | 2011 | 229 | 0.100 |
Why?
|
| Headache | 1 | 2011 | 73 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 141 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2012 | 182 | 0.090 |
Why?
|
| Ribavirin | 1 | 2010 | 57 | 0.090 |
Why?
|
| Hypothyroidism | 1 | 2012 | 232 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 859 | 0.090 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 161 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 999 | 0.090 |
Why?
|
| Waiting Lists | 2 | 2023 | 175 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2010 | 233 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2012 | 352 | 0.090 |
Why?
|
| Obesity, Morbid | 1 | 2012 | 225 | 0.090 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 98 | 0.090 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 376 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2012 | 265 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 159 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2012 | 971 | 0.080 |
Why?
|
| Hepatocytes | 2 | 2022 | 127 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 363 | 0.080 |
Why?
|
| Viscera | 1 | 2008 | 17 | 0.080 |
Why?
|
| Intra-Abdominal Fat | 2 | 2019 | 29 | 0.080 |
Why?
|
| Hepatitis C | 1 | 2010 | 208 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1196 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2019 | 2767 | 0.080 |
Why?
|
| Primary Health Care | 2 | 2022 | 339 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 104 | 0.080 |
Why?
|
| Cytokines | 1 | 2011 | 776 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2019 | 2601 | 0.080 |
Why?
|
| Organ Size | 1 | 2008 | 364 | 0.070 |
Why?
|
| Blood Glucose | 2 | 2018 | 873 | 0.070 |
Why?
|
| Mice, Inbred Strains | 2 | 2004 | 307 | 0.070 |
Why?
|
| Reproductive Behavior | 1 | 2006 | 1 | 0.070 |
Why?
|
| Cholagogues and Choleretics | 1 | 2006 | 10 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2010 | 510 | 0.070 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2006 | 23 | 0.070 |
Why?
|
| Reference Values | 2 | 2019 | 674 | 0.070 |
Why?
|
| Brain Edema | 1 | 2006 | 50 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1673 | 0.070 |
Why?
|
| Intracranial Pressure | 1 | 2006 | 77 | 0.070 |
Why?
|
| Fertility | 1 | 2006 | 115 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 2705 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 927 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2008 | 240 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 865 | 0.070 |
Why?
|
| Peroxisome Proliferators | 1 | 2004 | 2 | 0.060 |
Why?
|
| PPAR alpha | 1 | 2004 | 10 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3092 | 0.060 |
Why?
|
| Skin | 1 | 2008 | 554 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2004 | 66 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2006 | 268 | 0.060 |
Why?
|
| Cation Transport Proteins | 1 | 2004 | 64 | 0.060 |
Why?
|
| Deficiency Diseases | 1 | 2004 | 10 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 241 | 0.060 |
Why?
|
| Hypertension | 1 | 2012 | 1141 | 0.060 |
Why?
|
| RNA | 1 | 2008 | 560 | 0.060 |
Why?
|
| Thyroid Hormone Receptors beta | 1 | 2024 | 81 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2003 | 70 | 0.060 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2003 | 15 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 2004 | 228 | 0.060 |
Why?
|
| Fasting | 1 | 2004 | 161 | 0.060 |
Why?
|
| Endoscopy, Digestive System | 1 | 2003 | 65 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2006 | 373 | 0.060 |
Why?
|
| Angiography | 1 | 2003 | 208 | 0.050 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 35 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 338 | 0.050 |
Why?
|
| Research | 1 | 2023 | 253 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2022 | 150 | 0.050 |
Why?
|
| Pruritus | 1 | 2021 | 26 | 0.050 |
Why?
|
| Abdomen | 1 | 2022 | 122 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2021 | 153 | 0.050 |
Why?
|
| Glucose | 1 | 2004 | 638 | 0.050 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 9 | 0.050 |
Why?
|
| Models, Economic | 1 | 2020 | 60 | 0.050 |
Why?
|
| Markov Chains | 1 | 2020 | 125 | 0.050 |
Why?
|
| Portal Pressure | 1 | 2019 | 3 | 0.050 |
Why?
|
| Galectins | 1 | 2019 | 9 | 0.050 |
Why?
|
| Receptors, CCR2 | 1 | 2019 | 35 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 138 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 1135 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2019 | 144 | 0.040 |
Why?
|
| Length of Stay | 1 | 2022 | 702 | 0.040 |
Why?
|
| Northwestern United States | 1 | 2018 | 6 | 0.040 |
Why?
|
| Health Services | 1 | 2019 | 55 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 429 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 298 | 0.040 |
Why?
|
| Radiography, Abdominal | 1 | 2019 | 71 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 176 | 0.040 |
Why?
|
| Life Expectancy | 1 | 2019 | 86 | 0.040 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2019 | 59 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 172 | 0.040 |
Why?
|
| Health Resources | 1 | 2019 | 76 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2023 | 395 | 0.040 |
Why?
|
| Insulin | 1 | 2004 | 1160 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 48 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 303 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 746 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 916 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 454 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2018 | 224 | 0.040 |
Why?
|
| Glycosylation | 1 | 2017 | 129 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2017 | 20 | 0.040 |
Why?
|
| Liver Failure | 1 | 2017 | 78 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2017 | 179 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2017 | 75 | 0.040 |
Why?
|
| Premenopause | 1 | 2017 | 54 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 752 | 0.040 |
Why?
|
| Collagen | 1 | 2018 | 269 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1565 | 0.040 |
Why?
|
| Lipoproteins, HDL | 1 | 2017 | 96 | 0.040 |
Why?
|
| Multidetector Computed Tomography | 1 | 2017 | 54 | 0.040 |
Why?
|
| Overweight | 1 | 2017 | 118 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2021 | 376 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2019 | 219 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2018 | 408 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 327 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1863 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 814 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 567 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 217 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 911 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 350 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 350 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 187 | 0.030 |
Why?
|
| Medicare | 1 | 2017 | 410 | 0.030 |
Why?
|
| Calorimetry, Indirect | 1 | 2011 | 15 | 0.030 |
Why?
|
| Cholesterol, Dietary | 1 | 2011 | 27 | 0.030 |
Why?
|
| Prealbumin | 1 | 2011 | 34 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2232 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2011 | 93 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2011 | 61 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 2011 | 124 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2011 | 130 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 315 | 0.020 |
Why?
|
| Viral Load | 1 | 2010 | 148 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2010 | 327 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2011 | 271 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 712 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 1014 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1540 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 1851 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 797 | 0.020 |
Why?
|
| Catecholamine Plasma Membrane Transport Proteins | 1 | 2004 | 1 | 0.020 |
Why?
|
| Phenotype | 1 | 2011 | 2378 | 0.020 |
Why?
|
| Transfection | 1 | 2004 | 896 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 937 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 2468 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 1920 | 0.010 |
Why?
|